Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer | Zendy

Cora N. Sternberg | Zendy; Andrew J. Armstrong | Zendy; Роберто Пили | Zendy; Siobhan Ng | Zendy; Robert Huddart | Zendy; Neeraj Agarwal | Zendy; Denis Khvorostenko | Zendy; O. O. Lyulko | Zendy; Arija Brize | Zendy; Nicholas J. Vogelzang | Zendy; R. Delva | Zendy; Mihai Hârza | Zendy; A. Thanos | Zendy; Nicholas D. James | Zendy; Patrick Werbrouck | Zendy; Martin Bögemann | Zendy; Thomas E. Hutson | Zendy; Piotr Milecki | Zendy; Simon Chowdhury | Zendy; Enrique Gallardo | Zendy; Gilberto Schwartsmann | Zendy; Jean-Christophe Pouget | Zendy; Frédérique Baton | Zendy; Thore Nederman | Zendy; Helén Tuvesson | Zendy; Michael A. Carducci | Zendy

Open Access

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Cora N. Sternberg,

Andrew J. Armstrong,

Роберто Пили,

Siobhan Ng,

Robert Huddart,

Neeraj Agarwal,

Denis Khvorostenko,

O. O. Lyulko,

Arija Brize,

Nicholas J. Vogelzang,

R. Delva,

Mihai Hârza,

A. Thanos,

Nicholas D. James,

Patrick Werbrouck,

Martin Bögemann,

Thomas E. Hutson,

Piotr Milecki,

Simon Chowdhury,

Enrique Gallardo,

Gilberto Schwartsmann,

Jean-Christophe Pouget,

Frédérique Baton,

Thore Nederman,

Helén Tuvesson,

Michael A. Carducci

Publication year - 2016

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2016.66.9697

Subject(s) - medicine , prostate cancer , placebo , hazard ratio , clinical endpoint , progression free survival , urology , oncology , randomized controlled trial , cancer , chemotherapy , surgery , confidence interval , pathology , alternative medicine

Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research